These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1277 related articles for article (PubMed ID: 33599896)
1. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896 [TBL] [Abstract][Full Text] [Related]
2. Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis. Park T; Hwang M Expert Rev Cardiovasc Ther; 2024 Jun; 22(6):273-283. PubMed ID: 38722712 [TBL] [Abstract][Full Text] [Related]
3. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study. Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887 [TBL] [Abstract][Full Text] [Related]
4. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database. Welch HK; Kellum JA; Kane-Gill SL Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524 [TBL] [Abstract][Full Text] [Related]
5. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858 [TBL] [Abstract][Full Text] [Related]
6. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system. Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607 [TBL] [Abstract][Full Text] [Related]
7. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417 [TBL] [Abstract][Full Text] [Related]
8. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis. Zhou Z; Hultgren KE JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889 [TBL] [Abstract][Full Text] [Related]
9. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967 [TBL] [Abstract][Full Text] [Related]
10. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database. Yu M; Zhou L; Cao M; Ji C; Zheng Y Front Immunol; 2024; 15():1397692. PubMed ID: 39234238 [TBL] [Abstract][Full Text] [Related]
11. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868 [TBL] [Abstract][Full Text] [Related]
12. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database. Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423 [TBL] [Abstract][Full Text] [Related]
13. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events. Li Y; Sun S; Wu H; Zhao L; Peng W BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280 [TBL] [Abstract][Full Text] [Related]
14. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291 [TBL] [Abstract][Full Text] [Related]
15. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421 [TBL] [Abstract][Full Text] [Related]
16. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System. Battini V; Carnovale C; Clementi E; Sessa M Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948 [TBL] [Abstract][Full Text] [Related]
17. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis. Jiang A; Wei C; Zhu W; Wu F; Wu B Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707 [TBL] [Abstract][Full Text] [Related]
18. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database. Yang Q; Wang J; Wang M; Zhang S; He QQ BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168 [TBL] [Abstract][Full Text] [Related]
19. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712 [TBL] [Abstract][Full Text] [Related]
20. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]